Newronika

Newronika is a pioneering medical device company commercializing a next-generation, adaptive deep brain stimulation (αDBS) system for Parkinson's disease. Its technology differentiates itself from conventional DBS by using a closed-loop system that continuously senses brain signals and automatically adjusts stimulation, aiming to improve symptom control while reducing side effects. The company has achieved CE Mark approval in Europe and is generating early revenue through commercial sales, supported by compelling clinical data showing strong patient preference. Newronika is positioned to challenge the standard of care in neuromodulation with its intelligent, data-driven platform.

Adaptive, closed-loop deep brain stimulation (aDBS) system featuring a patented proportional control algorithm, full-spectrum brain sensing, and the WebBioBank™ cloud-based neural data platform for continuous therapy optimization.

Newronika competes in the DBS market dominated by large medical device companies like Medtronic, Boston Scientific, and Abbott, which offer conventional (open-loop) systems. Its direct competitors are other firms developing adaptive/closed-loop DBS, such as Bioinduction (owned by Zimmer Biomet) with its Picostim-DyNeuMo system. Newronika's CE Mark gives it a first-mover advantage in Europe for commercial adaptive DBS.